html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:19221692

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.

Journal of neural transmission (Vienna, Austria2009The record ↗

huperzine A

raisesMini-Mental State Examination total score

What moved

1 findingHow to read these marks →

Increases Mini-Mental State Examination total score
very limited
“Oral administration of HupA for 8-24 weeks (300-500 microg daily) led to significant improvements in MMSE and ADL.”
Study
meta-analysis
Dose studied
300-500 microg daily, oral, 8-24 weeks
Population
Patients with Alzheimer's disease; meta-analysis of four randomized trials comparing huperzine A with placebo

Study record

Design: meta-analysis
Species: human
Population: patients with Alzheimer's disease in four randomized trials of huperzine A versus placebo (abstract only)
Participants: not reported
Comparator: placebo
Duration: not reported
Endpoints measured: 4